New Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
15 Aug 2024
15 Aug 2024
Historique:
received:
14
05
2024
accepted:
19
07
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
aheadofprint
Résumé
The inhibition of renal transport proteins organic cation transporter 2 (OCT2), multidrug and toxin extrusion proteins (MATE1, MATE2-K), and organic anion transporters (OAT1, OAT3) causes clinically relevant drug-drug interactions (DDI). Endogenous biomarkers could be used to improve risk prediction of such renal DDIs. While a number of biomarkers for renal DDIs have been described so far, multiple criteria for valid biomarkers have frequently not been investigated, for example, specificity, metabolism, or food effects. Therefore, there is a need for novel biomarkers of renal DDIs. Here, we investigated the global metabolomic effects following the administration of two classical inhibitors of renal transport proteins [cimetidine (OCT2/MATEs), probenecid (OATs)] in human plasma and urine of healthy volunteers. Additionally, we investigated metabolomic effects of two inhibitors of other transporters [verapamil (P-glycoprotein), rifampin (organic anion transporting polypeptides)] as controls. This analysis shows that both cimetidine and probenecid affect compounds involved in caffeine metabolism, carnitines, and sulfates. Hierarchical cluster analysis of the effects of all four inhibitors on endogenous compounds identified multiple promising new sensitive and specific biomarker candidates for OCT2/MATE- or OAT-mediated DDIs. For OCT2/MATEs, 5-amino valeric acid betaine (median log
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Gessner, A., König, J. & Fromm, M.F. Clinical aspects of transporter‐mediated drug‐drug interactions. Clin Pharmacol Ther 105, 1386–1394 (2019).
Giacomini, K.M., Galetin, A. & Huang, S.M. The international transporter consortium: summarizing advances in the role of transporters in drug development. Clin Pharmacol Ther 104, 766–771 (2018).
Koepsell, H. Organic cation transporters in health and disease. Pharmacol Rev 72, 253–319 (2020).
Huo, X. & Liu, K. Renal organic anion transporters in drug‐drug interactions and diseases. Eur J Pharm Sci 112, 8–19 (2018).
Jala, A. et al. Transporter‐mediated drug‐drug interactions: advancement in models, analytical tools, and regulatory perspective. Drug Metab Rev 53, 285–320 (2021).
Mochizuki, T., Mizuno, T., Maeda, K. & Kusuhara, H. Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. Drug Metab Pharmacokinet 37, 100358 (2021).
European Medicines Agency (EMA). Guideline on the investigation of drug interactions <https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐investigation‐drug‐interactions‐revision‐1_en.pdf> (2012). Accessed January 18, 2024.
US Food and Drug Administration (FDA). Clinical drug interaction studies – cytochrome P450 enzyme‐ and transporter‐mediated drug interactions. Guidance for industry <https://www.fda.gov/media/134581/download> (2020). Accessed January 18, 2024.
US Food and Drug Administration (FDA). In vitro drug interaction studies – cytochrome P450 enzyme‐ and transporter‐mediated drug interactions. Guidance for industry <https://www.fda.gov/media/134582/download> (2020). Accessed January 18, 2024.
Brouwer, K.L. et al. In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther 94, 95–112 (2013).
Giacomini, K.M. et al. Membrane transporters in drug development. Nat Rev Drug Discov 9, 215–236 (2010).
Tweedie, D. et al. Transporter studies in drug development: experience to date and follow‐up on decision trees from the international transporter consortium. Clin Pharmacol Ther 94, 113–125 (2013).
Müller, F., Sharma, A., König, J. & Fromm, M.F. Biomarkers for in vivo assessment of transporter function. Pharmacol Rev 70, 246–277 (2018).
Galetin, A. et al. Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov 23, 255–280 (2024).
Li, Y., Talebi, Z., Chen, X., Sparreboom, A. & Hu, S. Endogenous biomarkers for SLC transporter‐mediated drug‐drug interaction evaluation. Molecules 26, 5500–5516 (2021).
Chu, X. et al. Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium. Clin Pharmacol Ther 104, 836–864 (2018).
Thakur, A., Saradhi, M.V., Singh, D.K. & Prasad, B. Effect of probenecid on blood levels and renal elimination of furosemide and endogenous compounds in rats: discovery of putative organic anion transporter biomarkers. Biochem Pharmacol 218, 115867 (2023).
Ailabouni, A.S., Mettu, V.S., Thakur, A., Singh, D.K. & Prasad, B. Effect of cimetidine on metformin pharmacokinetics and endogenous metabolite levels in rats. Drug Metab Dispos 52, 86–94 (2024).
Nies, A.T. et al. Novel drug transporter substrates identification: an innovative approach based on metabolomic profiling, in silico ligand screening and biological validation. Pharmacol Res 196, 106941–106950 (2023).
Bush, K.T., Wu, W., Lun, C. & Nigam, S.K. The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut‐liver‐kidney axis. J Biol Chem 292, 15789–15803 (2017).
Miyake, T. et al. Elucidation of N1‐methyladenosine as a potential surrogate biomarker for drug interaction studies involving renal organic cation transporters. Drug Metab Dispos 47, 1270–1280 (2019).
Kato, K. et al. Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. Pharm Res 31, 136–147 (2014).
Tsuruya, Y. et al. Investigation of endogenous compounds applicable to drug‐drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans. Drug Metab Dispos 44, 1925–1933 (2016).
Granados, J.C., Bhatnagar, V. & Nigam, S.K. Blockade of organic anion transport in humans after treatment with the drug probenecid leads to major metabolic alterations in plasma and urine. Clin Pharmacol Ther 112, 653–664 (2022).
Gessner, A. et al. A metabolomic analysis of sensitivity and specificity of 23 previously proposed biomarkers for renal transporter‐mediated drug‐drug interactions. Clin Pharmacol Ther 114, 1058–1072 (2023).
Wiebe, S.T. et al. Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine. Clin Pharmacokinet 59, 1627–1639 (2020).
Müller, F. et al. N1‐methylnicotinamide as biomarker for MATE‐mediated renal drug‐drug interactions: impact of cimetidine, rifampin, verapamil, and probenecid. Clin Pharmacol Ther 113, 1070–1079 (2023).
Wishart, D.S. et al. HMDB 5.0: the human metabolome database for 2022. Nucleic Acids Res 50, D622–D631 (2022).
Schymanski, E.L. et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol 48, 2097–2098 (2014).
Strauss, T. & von Maltitz, M.J. Generalising Ward's method for use with Manhattan distances. PLoS One 12, e0168288 (2017).
Lu, Y., Pang, Z. & Xia, J. Comprehensive investigation of pathway enrichment methods for functional interpretation of LC‐MS global metabolomics data. Brief Bioinform 24, 1–15 (2023).
Jewison, T. et al. SMPDB 2.0: big improvements to the small molecule pathway database. Nucleic Acids Res 42, 478–484 (2014).
Zhao, M. et al. Gut microbiota production of trimethyl‐5‐aminovaleric acid reduces fatty acid oxidation and accelerates cardiac hypertrophy. Nat Commun 13, 1757 (2022).
Kärkkäinen, O. et al. Whole grain intake associated molecule 5‐aminovaleric acid betaine decreases beta‐oxidation of fatty acids in mouse cardiomyocytes. Sci Rep 8, 13036 (2018).
Müller, F. et al. N1‐methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin‐trimethoprim interaction. Eur J Clin Pharmacol 71, 85–94 (2015).
Miyake, T. et al. Identification of appropriate endogenous biomarker for risk assessment of multidrug and toxin extrusion protein‐mediated drug‐drug interactions in healthy volunteers. Clin Pharmacol Ther 109, 507–516 (2021).
Rižner, T.L., Thalhammer, T. & Özvegy‐Laczka, C. The importance of steroid uptake and intracrine action in endometrial and ovarian cancers. Front Pharmacol 8, 346 (2017).
Ree, R., Varland, S. & Arnesen, T. Spotlight on protein N‐terminal acetylation. Exp Mol Med 50, 1–13 (2018).
Sass, J.O. et al. Mutations in ACY1, the gene encoding aminoacylase 1, cause a novel inborn error of metabolism. Am J Hum Genet 78, 401–409 (2006).
Tanaka, H., Sirich, T.L., Plummer, N.S., Weaver, D.S. & Meyer, T.W. An enlarged profile of uremic solutes. PLoS One 10, e0135657 (2015).
Granados, J.C. et al. Regulation of human endogenous metabolites by drug transporters and drug metabolizing enzymes: an analysis of targeted SNP‐metabolite associations. Meta 13, 171–194 (2023).
Kim, K.A., Oh, S.O., Park, P.W. & Park, J.Y. Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol 61, 275–280 (2005).
Ha, H.R., Chen, J., Krähenbühl, S. & Follath, F. Biotransformation of caffeine by cDNA‐expressed human cytochromes P‐450. Eur J Clin Pharmacol 49, 309–315 (1996).
Guo, J. et al. Metabolism and mechanism of human cytochrome P450 enzyme 1A2. Curr Drug Metab 22, 40–49 (2021).
Böhmer, G.M., Gleiter, C.H., Mörike, K., Nassr, N., Walz, A. & Lahu, G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol 51, 594–602 (2011).
Johnston, D.E. & Kroening, C. Mechanism of early carbon tetrachloride toxicity in cultured rat hepatocytes. Pharmacol Toxicol 83, 231–239 (1998).
Ermakov, V.S., Granados, J.C. & Nigam, S.K. Remote effects of kidney drug transporter OAT1 on gut microbiome composition and urate homeostasis. JCI Insight 8, e172341 (2023).